Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Norikazu Tanabe"'
Autor:
Yuki Kunimune, Yutaka Suehiro, Issei Saeki, Yurika Yamauchi, Norikazu Tanabe, Toshihiko Matsumoto, Shingo Higaki, Ikuei Fujii, Chieko Suzuki, Naoko Okayama, Mitsuaki Nishioka, Kiyoshi Ichihara, Hiroaki Nagano, Isao Sakaida, Taro Takami, Takahiro Yamasaki
Publikováno v:
Liver Cancer (2024)
Background: Patients with hepatitis virus-related hepatocellular carcinoma (viral HCC) are decreasing as hepatitis control improves, but those with non-viral-related HCC (non-viral HCC) are increasing in Japan. No established surveillance system exis
Externí odkaz:
https://doaj.org/article/a0703f6b2ca94c5297d352e3e8d34602
Autor:
Takahiro Yamasaki, Issei Saeki, Yurika Kotoh-Yamauchi, Ryo Sasaki, Norikazu Tanabe, Takashi Oono, Takashi Matsuda, Takuro Hisanaga, Toshihiko Matsumoto, Isao Hidaka, Tsuyoshi Ishikawa, Taro Takami, Yutaka Suehiro, Isao Sakaida
Publikováno v:
Applied Sciences, Vol 11, Iss 4, p 1882 (2021)
Recent success of systemic therapeutic agents, including combination immunotherapy, could promote a change in the treatment strategy in patients with advanced hepatocellular carcinoma (HCC). Although hepatic arterial infusion chemotherapy (HAIC) is a
Externí odkaz:
https://doaj.org/article/b213dda1a9c04699bbb481c329b4615e
Autor:
Yurika Kotoh, Issei Saeki, Takahiro Yamasaki, Ryo Sasaki, Norikazu Tanabe, Takashi Oono, Takashi Matsuda, Takuro Hisanaga, Toshihiko Matsumoto, Isao Hidaka, Tsuyoshi Ishikawa, Taro Takami, Isao Sakaida
Publikováno v:
Applied Sciences, Vol 10, Iss 16, p 5403 (2020)
Previous studies have reported prognostic factors for hepatocellular carcinoma (HCC) patients receiving lenvatinib; however, no studies have evaluated the effects of both handgrip strength and skeletal muscle mass on the clinical outcomes. Therefore,
Externí odkaz:
https://doaj.org/article/b3b9f4a41694455eb0bc96deb80ae6c9
Autor:
Issei Saeki, Takahiro Yamasaki, Norikazu Tanabe, Takuya Iwamoto, Toshihiko Matsumoto, Yohei Urata, Isao Hidaka, Tsuyoshi Ishikawa, Taro Takami, Naoki Yamamoto, Koichi Uchida, Shuji Terai, Isao Sakaida
Publikováno v:
PLoS ONE, Vol 10, Iss 5, p e0126649 (2015)
Hepatic arterial infusion chemotherapy (HAIC) is an option for treating advanced hepatocellular carcinoma (HCC). Because of the poor prognosis in HAIC non-responders, it is important to identify patients who may benefit from continuous HAIC treatment
Externí odkaz:
https://doaj.org/article/7c409cb3ff864ea3a3faf149a42afd8a
Autor:
Tsuyoshi Ishikawa, Maho Egusa, Tsuyoshi Fujioka, Natsuko Nishiyama, Daiki Kawamoto, Ryo Sasaki, Tatsuro Nishimura, Norikazu Tanabe, Takashi Oono, Issei Saeki, Taro Takami
Publikováno v:
Journal of Gastroenterology. 58:246-256
We previously reported liver stiffness (LS) as a prognostic predictor of portosystemic shunt (PSS) occlusion. This study aims to reinvestigate the predictive factors of the model for end-stage liver disease-sodium (MELD-Na) score amelioration followi
Autor:
Norikazu Tanabe, Issei Saeki, Yuki Aibe, Takashi Matsuda, Tadasuke Hanazono, Maiko Nishi, Isao Hidaka, Shinya Kuwashiro, Shogo Shiratsuki, Keiji Matsuura, Maho Egusa, Natsuko Nishiyama, Tsuyoshi Fujioka, Daiki Kawamoto, Ryo Sasaki, Tatsuro Nishimura, Takashi Oono, Takuro Hisanaga, Toshihiko Matsumoto, Tsuyoshi Ishikawa, Takahiro Yamasaki, Taro Takami
Publikováno v:
Cancers; Volume 15; Issue 11; Pages: 2927
Despite the promising efficacy of atezolizumab plus bevacizumab (atezo/bev), some patients with unresectable hepatocellular carcinoma (HCC) experience disease progression. This retrospective study, which included 154 patients, aimed to evaluate predi
Autor:
Issei Saeki, Yutaka Suehiro, Yurika Yamauchi, Tomomi Hoshida, Norikazu Tanabe, Takashi Oono, Daiki Kawamoto, Tatsuro Nishimura, Toshihiko Matsumoto, Tsuyoshi Ishikawa, Mototsugu Shimokawa, Akihiro Tamori, Norifumi Kawada, Yasuyuki Tamai, Motoh Iwasa, Hayato Nakagawa, Hiroaki Nagano, Taro Takami, Takahiro Yamasaki
Publikováno v:
Hepatology International.
Autor:
Yurika Yamauchi, Issei Saeki, Takahiro Yamasaki, Maho Egusa, Natsuko Nishiyama, Tsuyoshi Fujioka, Daiki Kawamoto, Tatsuro Nishimura, Norikazu Tanabe, Takashi Oono, Toshihiko Matsumoto, Tsuyoshi Ishikawa, Yoshio Marumoto, Satoshi Matsukuma, Yoshitaro Shindo, Yukio Tokumitsu, Sota Yoshimine, Junichi Murakami, Toshiki Tanaka, Sotai Kimura, Yoshinobu Hoshii, Kimikazu Hamano, Hiroaki Nagano, Taro Takami
Publikováno v:
Hepatology Research.
Autor:
Hideto Kawaratani, Yasuteru Kondo, Ryoji Tatsumi, Naoto Kawabe, Norikazu Tanabe, Akira Sakamaki, Kazuo Okumoto, Yoshihito Uchida, Kei Endo, Takumi Kawaguchi, Tsunekazu Oikawa, Yoji Ishizu, Shuhei Hige, Taro Takami, Shuji Terai, Yoshiyuki Ueno, Satoshi Mochida, Yasuhiro Takikawa, Takuji Torimura, Tomokazu Matsuura, Masatoshi Ishigami, Kazuhiko Koike, Hitoshi Yoshiji
Publikováno v:
Journal of Clinical Medicine; Volume 11; Issue 6; Pages: 1571
Background: Rifaximin is commonly used for hepatic encephalopathy (HE). However, the effects of long-term treatment for Japanese people are limited. Therefore, this study aimed to investigate the effects and safety of long-term treatment with rifaxim
Autor:
Taro Takami, Takashi Oono, Issei Saeki, Isao Hidaka, Takahiro Yamasaki, Norikazu Tanabe, Ryo Sasaki, Takashi Matsuda, Isao Sakaida, Yurika Kotoh-Yamauchi, Toshihiko Matsumoto, Tsuyoshi Ishikawa, Takuro Hisanaga, Yutaka Suehiro
Publikováno v:
Applied Sciences, Vol 11, Iss 1882, p 1882 (2021)
Recent success of systemic therapeutic agents, including combination immunotherapy, could promote a change in the treatment strategy in patients with advanced hepatocellular carcinoma (HCC). Although hepatic arterial infusion chemotherapy (HAIC) is a